Antibody seroconversion rate (≥ 4-fold increase from baseline) against SARS-CoV-2 neutralising antibodies 29 days post second vaccination.;Incidence of local and systemic solicited AEs for 7 days following each vaccination (Day 1 through Day 7 for first vaccination and Day 29 through Day 35 for second vaccination).;Incidence of unsolicited AEs, SAEs and AESIs through 29 days post each vaccination (ie, until Day 29 following the first vaccination and Day 57 following the second vaccination).

Antibody seroconversion rate (≥ 4-fold increase from baseline) against SARS-CoV-2 neutralising antibodies 29 days post second vaccination.;Incidence of local and systemic solicited AEs for 7 days following each vaccination (Day 1 through Day 7 for first vaccination and Day 29 through Day 35 for second vaccination).;Incidence of unsolicited AEs, SAEs and AESIs through 29 days post each vaccination (ie, until Day 29 following the first vaccination and Day 57 following the second vaccination).

Antibody seroconversion rate (≥ 4-fold increase from baseline) against SARS-CoV-2 Spike protein 29 days post second vaccination.

Antibody seroconversion rate (≥ 4-fold increase from baseline) against SARS-CoV-2 Spike protein 29 days post second vaccination.

Incidence of local and systemic solicited AEs for 7 days post each dose Incidence of unsolicited AEs for 28 days post each dose Incidence of SAEs and AESIs to 28 days post second dose;The proportion of participants who have a post treatment seroresponse (≥ 4-fold rise in titres from Day 1 baseline value) to Spike antigen (MSD serology assay) at Day 57

Incidence of local and systemic solicited AEs for 7 days post each dose Incidence of unsolicited AEs for 28 days post each dose Incidence of SAEs and AESIs to 28 days post second dose;The proportion of participants who have a post treatment seroresponse (≥ 4-fold rise in titres from Day 1 baseline value) to Spike antigen (MSD serology assay) at Day 57